Session » Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes III: Long Live (Comorbidity and Outcomes) (2681–2686)

Date: Wednesday, October 29, 2025

Time: 11:30AM-1:00PM

Meeting: ACR Convergence 2025

11:30AM-11:45AM: Abstract Number: 2681

Derivation and Validation of Inflammation-Adjusted Lipid Measures to Improve Cardiovascular Risk Prediction in Rheumatoid Arthritis

11:45AM-12:00PM: Abstract Number: 2682

Methotrexate use and higher age impair humoral response against the recombinant herpes zoster vaccine (RZV) in Rheumatoid Arthritis: a prospective, randomized, placebo-controlled trial

12:00PM-12:15PM: Abstract Number: 2683

Association of Genetic Risk for Pain Intensity with Longitudinal Disease Activity in Rheumatoid Arthritis

12:15PM-12:30PM: Abstract Number: 2684

Multimodal Analysis Revealed Altered Brain Connectivity Patterns and Neuroinflammatory Processes in the Background of Difficult-To-Treat Rheumatoid Arthritis

12:30PM-12:45PM: Abstract Number: 2685

Assessing for Racial/Ethnic Variability in U.S.-FRAXTM Performance Among Older Adult Women with Rheumatoid Arthritis in the United States

12:45PM-1:00PM: Abstract Number: 2686

Impact of autoimmunity, disease activity and treatment on the time course of bone density, microstructure and biomechanics in inflammatory arthritis.

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].